SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

Braftovi

PFE·PFIZER INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already marketed. Braftovi has been commercially available since its initial FDA approval in June 2018.
Why 3/10
No scheduled PDUFA date, pivotal readout, or other hard binary catalyst for Braftovi in the next ~12 months. The drug is already approved across three indications and is one of many products in Pfizer's massive portfolio (2026 revenue guidance $62-64B). Without a pending regulatory decision, impactScore cannot exceed 5 per the rubric, and the lack of any dated catalyst plus the drug's small share of Pfizer's overall value places it at 3.
Actionable Insight NEUTRAL

Braftovi has no scheduled PDUFA dates or pivotal readouts in the next 12 months; the next catalyst to watch is whether Pfizer pursues a label expansion for the FOLFIRI chemotherapy backbone based on the positive BREAKWATER Cohort 3 data presented at ASCO 2026. For a company the size of Pfizer, Braftovi is a steady commercial contributor but not a standalone stock-moving catalyst.

Price Chart

Loading chart...

Executive Summary

Braftovi (encorafenib) is an oral BRAF kinase inhibitor originally approved by the FDA in June 2018 for BRAF-mutant melanoma. It has since expanded to three approved U.S. indications: melanoma (2018, with binimetinib), metastatic non-small cell lung cancer (October 2023, with binimetinib), and metastatic colorectal cancer (accelerated approval December 2024, converted to full approval February 2026, with cetuximab and chemotherapy). The drug is developed and commercialized by Array BioPharma, a wholly owned subsidiary of Pfizer Inc. (NYSE: PFE). Braftovi is a mature, multi-indication product within Pfizer's massive oncology portfolio and faces no near-term binary regulatory catalysts.

How It Works

Braftovi is a targeted cancer pill that blocks a mutated protein called BRAF, which is found in some cancers and acts like a stuck 'on' switch that tells cancer cells to grow. By turning off this switch, Braftovi slows or stops tumor growth. It is often combined with another drug (binimetinib, sold as Mektovi) that blocks a related protein in the same growth pathway, making the treatment more effective and delaying resistance.

Trial Status

Braftovi is FDA-approved across three indications. The pivotal Phase 3 BREAKWATER trial (NCT04607421) supported the February 2026 full approval for first-line BRAF V600E-mutant metastatic colorectal cancer, showing a 51% reduction in risk of death and a 47% reduction in risk of disease progression with the encorafenib + cetuximab + mFOLFOX6 regimen. Cohort 3 of BREAKWATER, evaluating encorafenib + cetuximab + FOLFIRI, reported positive results at ASCO 2026 showing nearly doubled median progression-free survival versus standard of care. A Phase 2 trial (NCT05217446) of encorafenib + cetuximab + pembrolizumab in first-line mCRC is active but not recruiting (primary completion June 2026). Braftovi is also approved in Japan for BRAF V600-mutated thyroid cancer based on a Phase 2 study.

The Two-Sided Case

▲ Bull Case4
Braftovi has three FDA-approved indications (melanoma, NSCLC, mCRC) with strong clinical data, including a 51% reduction in death risk from the Phase 3 BREAKWATER trial.
The drug is forecast to command a 42% share of the BRAF inhibitors melanoma market by 2028, per GlobalData.
Positive Cohort 3 BREAKWATER data (nearly doubled PFS with FOLFIRI backbone) could support further label expansion and broaden the addressable patient population.
Braftovi is part of Pfizer's growing oncology portfolio, which contributed to 32% operational growth in launched and acquired products in Q3 2026.
▼ Bear Case4
Braftovi is a small component of Pfizer's overall business (Pfizer's 2026 revenue guidance is $62-64B), so even strong commercial performance has limited impact on the stock.
The drug faces competition from other BRAF/MEK inhibitor combinations, including Novartis's Tafinlar + Mekinist and Roche's Zelboraf + Cotellic.
No near-term binary catalysts exist for Braftovi, making it a steady but unexciting holding for event-driven biotech investors.
Pfizer's stock has a consensus price target of $29.26 (below the current ~$30 price), with 18 hold ratings out of 34 analysts, reflecting limited upside expectations for the overall company.

Upcoming Catalysts

  • Potential FDA supplemental filing for FOLFIRI chemotherapy backbone based on BREAKWATER Cohort 3 data (timing not announced)
  • Ongoing Phase 2 trial of encorafenib + cetuximab + pembrolizumab in first-line mCRC (NCT05217446) - results expected

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 11

Hover a chip for the title
1 drugs.com2 fda.gov3 fda.gov4 pfizer.com5 pfizer.com6 pfizer.com7 globaldata.com8 pfizer.com9 cnbc.com10 accessdata.fda.gov11 pharmadossier.com